DexCom announced that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription at Stelo.com.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- QQQ ETF Update, 8/23/2024
- DexCom price target raised to $100 from $90 at Stifel
- DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP Before October 21, 2024 to Discuss Your Rights – DXCM
- Street analysts say diabetes stocks âoverreactingâ to Lilly GLP-1 study results
- Diabetes stock selloff on Lilly Surmount-1 results overdone, says Citi